{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:09:13Z","timestamp":1793225353236,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006458","name":"Children&apos;s Hospital of Philadelphia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60000-3","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:08:46Z","timestamp":1747674526000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Optimized AAV capsids for basal ganglia diseases show robust potency and distribution"],"prefix":"10.1038","volume":"16","author":[{"given":"D. E.","family":"Leib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. H.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-3544","authenticated-orcid":false,"given":"L.","family":"Tecedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. T.","family":"Ranum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9055-6874","authenticated-orcid":false,"given":"M. S.","family":"Keiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. C.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Carrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Huerta-Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4203-3391","authenticated-orcid":false,"given":"D.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. M.","family":"Fluta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. L.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"60000_CR1","doi-asserted-by":"publisher","first-page":"988914","DOI":"10.3389\/fnmol.2022.988914","volume":"15","author":"K Zhou","year":"2022","unstructured":"Zhou, K., Han, J., Wang, Y., Zhang, Y. & Zhu, C. Routes of administration for adeno-associated viruses carrying gene therapies for brain diseases. Front. Mol. Neurosci. 15, 988914 (2022).","journal-title":"Front. Mol. Neurosci."},{"key":"60000_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3171\/2020.4.JNS20701","volume":"134","author":"RR Lonser","year":"2020","unstructured":"Lonser, R. R., Akhter, A. S., Zabek, M., Elder, J. B. & Bankiewicz, K. S. Direct convective delivery of adeno-associated virus gene therapy for treatment of neurological disorders. J. Neurosurg. 134, 1751\u20131763 (2020).","journal-title":"J. Neurosurg."},{"key":"60000_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust, K. D. et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59\u201365 (2009).","journal-title":"Nat. Biotechnol."},{"key":"60000_CR4","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1038\/mt.2011.98","volume":"19","author":"H Zhang","year":"2011","unstructured":"Zhang, H. et al. Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system. Mol. Ther. 19, 1440\u20131448 (2011).","journal-title":"Mol. Ther."},{"key":"60000_CR5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"60000_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan, K. Y. et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat. Neurosci. 20, 1172\u20131179 (2017).","journal-title":"Nat. Neurosci."},{"key":"60000_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41593-021-00969-4","volume":"25","author":"D Goertsen","year":"2022","unstructured":"Goertsen, D. et al. AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset. Nat. Neurosci. 25, 106\u2013115 (2022).","journal-title":"Nat. Neurosci."},{"key":"60000_CR8","doi-asserted-by":"crossref","unstructured":"Huang, Q. et al. An AAV capsid reprogrammed to bind human Transferrin Receptor mediates brain-wide gene delivery. Science. 384, 1220\u20131227 (2024).","DOI":"10.1126\/science.adm8386"},{"key":"60000_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.medj.2022.11.002","volume":"4","author":"AC Stanton","year":"2023","unstructured":"Stanton, A. C. et al. Systemic administration of novel engineered AAV capsids facilitates enhanced transgene expression in the macaque CNS. Med 4, 31\u201350 e38 (2023).","journal-title":"Med"},{"key":"60000_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/hum.2018.015","volume":"29","author":"C Hinderer","year":"2018","unstructured":"Hinderer, C. et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum. Gene Ther. 29, 285\u2013298 (2018).","journal-title":"Hum. Gene Ther."},{"key":"60000_CR11","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1016\/j.ymthe.2023.07.020","volume":"31","author":"E Hudry","year":"2023","unstructured":"Hudry, E. et al. Liver injury in cynomolgus monkeys following intravenous and intrathecal scAAV9 gene therapy delivery. Mol. Ther. 31, 2999\u20133014 (2023).","journal-title":"Mol. Ther."},{"key":"60000_CR12","doi-asserted-by":"publisher","first-page":"975803","DOI":"10.3389\/fimmu.2022.975803","volume":"13","author":"HCJ Ertl","year":"2022","unstructured":"Ertl, H. C. J. Immunogenicity and toxicity of AAV gene therapy. Front. Immunol. 13, 975803 (2022).","journal-title":"Front. Immunol."},{"key":"60000_CR13","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan, D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol. Ther. 31, 3123\u20133126 (2023).","journal-title":"Mol. Ther."},{"key":"60000_CR14","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-021-01483-7","volume":"27","author":"G Thomsen","year":"2021","unstructured":"Thomsen, G. et al. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue. Nat. Med. 27, 1701\u20131711 (2021).","journal-title":"Nat. Med."},{"key":"60000_CR15","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride, J. L. et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol. Ther. 19, 2152\u20132162 (2011).","journal-title":"Mol. Ther."},{"key":"60000_CR16","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/hum.2008.022","volume":"19","author":"S Worgall","year":"2008","unstructured":"Worgall, S. et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19, 463\u2013474 (2008).","journal-title":"Hum. Gene Ther."},{"key":"60000_CR17","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.1212\/WNL.0000000000012952","volume":"98","author":"CW Christine","year":"2022","unstructured":"Christine, C. W. et al. Safety of AADC gene therapy for moderately advanced Parkinson disease: Three-year outcomes from the PD-1101 trial. Neurology 98, e40\u2013e50 (2022).","journal-title":"Neurology"},{"key":"60000_CR18","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1089\/hum.2006.17.291","volume":"17","author":"P Hadaczek","year":"2006","unstructured":"Hadaczek, P. et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum. Gene Ther. 17, 291\u2013302 (2006).","journal-title":"Hum. Gene Ther."},{"key":"60000_CR19","doi-asserted-by":"crossref","unstructured":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971\u2013983 (1993).","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"60000_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5214\/ans.0972.7531.210308","volume":"21","author":"AA Rikani","year":"2014","unstructured":"Rikani, A. A. et al. The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann. Neurosci. 21, 112\u2013114 (2014).","journal-title":"Ann. Neurosci."},{"key":"60000_CR21","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.neuron.2023.12.009","volume":"112","author":"C Pressl","year":"2024","unstructured":"Pressl, C. et al. Selective vulnerability of layer 5a corticostriatal neurons in Huntington\u2019s disease. Neuron 112, 924\u2013941 (2024).","journal-title":"Neuron"},{"key":"60000_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35752-x","volume":"14","author":"A Matsushima","year":"2023","unstructured":"Matsushima, A. et al. Transcriptional vulnerabilities of striatal neurons in human and rodent models of Huntington\u2019s disease. Nat. Commun. 14, 282 (2023).","journal-title":"Nat. Commun."},{"key":"60000_CR23","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"SQ Harper","year":"2005","unstructured":"Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc. Natl. Acad. Sci. USA 102, 5820\u20135825 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60000_CR24","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"HB Kordasiewicz","year":"2012","unstructured":"Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron 74, 1031\u20131044 (2012).","journal-title":"Neuron"},{"key":"60000_CR25","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1038\/mtna.2015.7","volume":"4","author":"AM Monteys","year":"2015","unstructured":"Monteys, A. M., Wilson, M. J., Boudreau, R. L., Spengler, R. M. & Davidson, B. L. Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo. Mol. Ther. Nucleic Acids 4, e234 (2015).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"60000_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.neuron.2016.03.016","volume":"90","author":"J Ochaba","year":"2016","unstructured":"Ochaba, J. et al. PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington\u2019s Disease-Associated Phenotypes In Vivo. Neuron 90, 507\u2013520 (2016).","journal-title":"Neuron"},{"key":"60000_CR27","doi-asserted-by":"publisher","first-page":"e2021836118","DOI":"10.1073\/pnas.2021836118","volume":"118","author":"EL Morozko","year":"2021","unstructured":"Morozko, E. L. et al. PIAS1 modulates striatal transcription, DNA damage repair, and SUMOylation with relevance to Huntington\u2019s disease. Proc. Nat.l Acad. Sci. USA 118, e2021836118 (2021).","journal-title":"Proc. Nat.l Acad. Sci. USA"},{"key":"60000_CR28","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jconrel.2016.02.034","volume":"240","author":"KS Bankiewicz","year":"2016","unstructured":"Bankiewicz, K. S. et al. AAV viral vector delivery to the brain by shape-conforming MR-guided infusions. J. Control Release 240, 434\u2013442 (2016).","journal-title":"J. Control Release"},{"key":"60000_CR29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.neuron.2020.06.021","volume":"107","author":"H Lee","year":"2020","unstructured":"Lee, H. et al. Cell type-specific transcriptomics reveals that mutant huntingtin leads to mitochondrial RNA release and neuronal innate immune activation. Neuron 107, 891\u2013908 (2020).","journal-title":"Neuron"},{"key":"60000_CR30","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1089\/hum.2020.116","volume":"31","author":"DJ Ballon","year":"2020","unstructured":"Ballon, D. J. et al. Quantitative whole-body imaging of I-124-labeled adeno-associated viral vector biodistribution in nonhuman primates. Hum. Gene Ther. 31, 1237\u20131259 (2020).","journal-title":"Hum. Gene Ther."},{"key":"60000_CR31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1089\/hum.2020.167","volume":"31","author":"J Hordeaux","year":"2020","unstructured":"Hordeaux, J. et al. Adeno-associated virus-induced dorsal root ganglion pathology. Hum. Gene Ther. 31, 808\u2013818 (2020).","journal-title":"Hum. Gene Ther."},{"key":"60000_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/brainsci11020129","volume":"11","author":"EA Spronck","year":"2021","unstructured":"Spronck, E. A. et al. Intrastriatal administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in miHTT transgene expression in key areas of huntington disease pathology. Brain Sci. 11, 129 (2021).","journal-title":"Brain Sci."},{"key":"60000_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/gt.2017.14","volume":"24","author":"L Samaranch","year":"2017","unstructured":"Samaranch, L. et al. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther. 24, 253\u2013261 (2017).","journal-title":"Gene Ther."},{"key":"60000_CR34","doi-asserted-by":"publisher","first-page":"e948","DOI":"10.1002\/cpz1.948","volume":"3","author":"EA Waxman","year":"2023","unstructured":"Waxman, E. A. et al. Reproducible differentiation of human pluripotent stem cells into two-dimensional cortical neuron cultures with checkpoints for success. Curr. Protoc. 3, e948 (2023).","journal-title":"Curr. Protoc."},{"key":"60000_CR35","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuron.2013.05.029","volume":"78","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Rapid single-step induction of functional neurons from human pluripotent stem cells. Neuron 78, 785\u2013798 (2013).","journal-title":"Neuron"},{"key":"60000_CR36","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1002\/cpcb.51","volume":"79","author":"MS Fernandopulle","year":"2018","unstructured":"Fernandopulle, M. S. et al. Transcription factor-mediated differentiation of human iPSCs into neurons. Curr. Protoc. Cell Biol. 79, e51 (2018).","journal-title":"Curr. Protoc. Cell Biol."},{"key":"60000_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24524-8","volume":"12","author":"TS Pearson","year":"2021","unstructured":"Pearson, T. S. et al. Gene therapy for aromatic L-amino acid decarboxylase deficiency by MR-guided direct delivery of AAV2-AADC to midbrain dopaminergic neurons. Nat. Commun. 12, 4251 (2021).","journal-title":"Nat. Commun."},{"key":"60000_CR38","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.1016\/j.ymthe.2022.08.003","volume":"30","author":"MT Rocco","year":"2022","unstructured":"Rocco, M. T. et al. Long-term safety of MRI-guided administration of AAV2-GDNF and gadoteridol in the putamen of individuals with Parkinson\u2019s disease. Mol. Ther. 30, 3632\u20133638 (2022).","journal-title":"Mol. Ther."},{"key":"60000_CR39","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073\u20131080 (2008).","journal-title":"Mol. Ther."},{"key":"60000_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6 J mice. Mol. Ther. 26, 664\u2013668 (2018).","journal-title":"Mol. Ther."},{"key":"60000_CR41","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","volume":"27","author":"J Hordeaux","year":"2019","unstructured":"Hordeaux, J. et al. The GPI-Linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912\u2013921 (2019).","journal-title":"Mol. Ther."},{"key":"60000_CR42","doi-asserted-by":"publisher","first-page":"e0225206","DOI":"10.1371\/journal.pone.0225206","volume":"14","author":"Q Huang","year":"2019","unstructured":"Huang, Q. et al. Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. PLoS ONE 14, e0225206 (2019).","journal-title":"PLoS ONE"},{"key":"60000_CR43","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41565-023-01419-x","volume":"18","author":"MR Chuapoco","year":"2023","unstructured":"Chuapoco, M. R. et al. Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain. Nat. Nanotechnol. 18, 1241\u20131251 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"60000_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33745-4","volume":"13","author":"TJ Gonzalez","year":"2022","unstructured":"Gonzalez, T. J. et al. Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. Nat. Commun. 13, 5947 (2022).","journal-title":"Nat. Commun."},{"key":"60000_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52149-0","volume":"15","author":"TF Shay","year":"2024","unstructured":"Shay, T. F. et al. Human cell surface-AAV interactomes identify LRP6 as blood-brain barrier transcytosis receptor and immune cytokine IL3 as AAV9 binder. Nat. Commun. 15, 7853 (2024).","journal-title":"Nat. Commun."},{"key":"60000_CR46","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1126\/science.adm8386","volume":"384","author":"Q Huang","year":"2024","unstructured":"Huang, Q. et al. An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery. Science 384, 1220\u20131227 (2024).","journal-title":"Science"},{"key":"60000_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50555-y","volume":"15","author":"FE Eid","year":"2024","unstructured":"Eid, F. E. et al. Systematic multi-trait AAV capsid engineering for efficient gene delivery. Nat. Commun. 15, 6602 (2024).","journal-title":"Nat. Commun."},{"key":"60000_CR48","doi-asserted-by":"publisher","first-page":"eadj3786","DOI":"10.1126\/sciadv.adj3786","volume":"10","author":"D Zhu","year":"2024","unstructured":"Zhu, D. et al. Optimal trade-off control in machine learning-based library design, with application to adeno-associated virus (AAV) for gene therapy. Sci. Adv. 10, eadj3786 (2024).","journal-title":"Sci. Adv."},{"key":"60000_CR49","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1227\/00006123-199412000-00016","volume":"35","author":"J Siegfried","year":"1994","unstructured":"Siegfried, J. & Lippitz, B. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 35, 1126\u20131129 (1994).","journal-title":"Neurosurgery"},{"key":"60000_CR50","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","volume":"16","author":"DJH Moss","year":"2017","unstructured":"Moss, D. J. H. et al. Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study. Lancet Neurol. 16, 701\u2013711 (2017).","journal-title":"Lancet Neurol."},{"key":"60000_CR51","doi-asserted-by":"publisher","unstructured":"Davidson Lab CHOP and bclewandowski. DavidsonLabCHOP\/DB3_Publication_2025: DB3_Publication_2025 v1.0.0. Zenodo. https:\/\/doi.org\/10.5281\/zenodo.14851572 (2025).","DOI":"10.5281\/zenodo.14851572"},{"key":"60000_CR52","doi-asserted-by":"publisher","first-page":"118759","DOI":"10.1016\/j.neuroimage.2021.118759","volume":"245","author":"KS Saleem","year":"2021","unstructured":"Saleem, K. S. et al. High-resolution mapping and digital atlas of subcortical regions in the macaque monkey based on matched MAP-MRI and histology. Neuroimage 245, 118759 (2021).","journal-title":"Neuroimage"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60000-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60000-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T18:03:45Z","timestamp":1747677825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60000-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60000"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60000-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.T., Y.H.C., D.E.L., P.T.R., M.S.K., and B.L.D. are founders of Latus Bio and have stock options. D.E.L. and P.T.R. are employees of Latus Bio. B.L.D. has sponsored research or serves an advisory role for Carbon Bio, Resilience, Roche and Latus Bio. The other authors declare that they have no competing interests. A patent has been submitted; PCT\/US2023\/021905, \u2018Adeno-associated viral vectors for targeting deep brain structures\u2019, B.L.D., P.T.R., M.S.K., Y.H.C., L.T., and D.E.L.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4653"}}